Does the media refer more to DTIL or ANNX?

In the previous week, Precision BioSciences and Precision BioSciences both had 2 articles in the media. Annexon's average media sentiment score of 0.37 beat Precision BioSciences' score of 0.20 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VSTM or DTIL?

In the previous week, Verastem had 10 more articles in the media than Precision BioSciences. MarketBeat recorded 12 mentions for Verastem and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.20 beat Verastem's score of 0.13 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Precision BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NVCT or DTIL?

In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 2 articles in the media. Precision BioSciences' average media sentiment score of 0.20 beat Nuvectis Pharma's score of 0.08 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Precision BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IRWD or DTIL?

In the previous week, Ironwood Pharmaceuticals and Ironwood Pharmaceuticals both had 2 articles in the media. Ironwood Pharmaceuticals' average media sentiment score of 0.59 beat Precision BioSciences' score of 0.20 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SLN or DTIL?

In the previous week, Silence Therapeutics and Silence Therapeutics both had 2 articles in the media. Silence Therapeutics' average media sentiment score of 0.25 beat Precision BioSciences' score of 0.20 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precision BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Precision BioSciences (DTIL) Competitors

$6.36 -0.83 (-11.54%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$6.40 +0.04 (+0.57%)

As of 04:06 AM Eastern

Compare

DTIL vs. ANNX, VSTM, NVCT, IRWD, and SLN

Should you buy Precision BioSciences stock or one of its competitors? Precision BioSciences's main competitors and comparable companies include Annexon (ANNX), Verastem (VSTM), Nuvectis Pharma (NVCT), Ironwood Pharmaceuticals (IRWD), and Silence Therapeutics (SLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Precision BioSciences compare to Annexon?

Precision BioSciences (NASDAQ:DTIL) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Annexon has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -72.52% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Annexon	N/A	-106.15%	-79.82%

Precision BioSciences has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.06M	3.90	-$45.72M	-$2.80	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

Precision BioSciences currently has a consensus price target of $32.25, suggesting a potential upside of 407.08%. Annexon has a consensus price target of $15.14, suggesting a potential upside of 291.29%. Given Precision BioSciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Precision BioSciences is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Precision BioSciences and Precision BioSciences both had 2 articles in the media. Annexon's average media sentiment score of 0.37 beat Precision BioSciences' score of 0.20 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annexon	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precision BioSciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Annexon has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

38.0% of Precision BioSciences shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by company insiders. Comparatively, 10.3% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Precision BioSciences beats Annexon on 9 of the 14 factors compared between the two stocks.

How does Precision BioSciences compare to Verastem?

Verastem (NASDAQ:VSTM) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

88.4% of Verastem shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 1.9% of Verastem shares are owned by insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Precision BioSciences has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	23.97	-$209.47M	-$2.66	N/A
Precision BioSciences	$45.06M	3.90	-$45.72M	-$2.80	N/A

Precision BioSciences has a net margin of -96.73% compared to Verastem's net margin of -231.59%. Precision BioSciences' return on equity of -72.52% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Precision BioSciences	-96.73%	-72.52%	-32.25%

In the previous week, Verastem had 10 more articles in the media than Precision BioSciences. MarketBeat recorded 12 mentions for Verastem and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.20 beat Verastem's score of 0.13 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Precision BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verastem presently has a consensus price target of $13.83, indicating a potential upside of 69.11%. Precision BioSciences has a consensus price target of $32.25, indicating a potential upside of 407.08%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Verastem has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Summary

Precision BioSciences beats Verastem on 10 of the 17 factors compared between the two stocks.

How does Precision BioSciences compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Nuvectis Pharma currently has a consensus price target of $36.25, suggesting a potential upside of 72.05%. Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 407.08%. Given Precision BioSciences' higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Nuvectis Pharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Nuvectis Pharma has higher earnings, but lower revenue than Precision BioSciences. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Precision BioSciences	$45.06M	3.90	-$45.72M	-$2.80	N/A

Nuvectis Pharma has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -72.52% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Precision BioSciences	-96.73%	-72.52%	-32.25%

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by company insiders. Comparatively, 2.7% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 2 articles in the media. Precision BioSciences' average media sentiment score of 0.20 beat Nuvectis Pharma's score of 0.08 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precision BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Precision BioSciences beats Nuvectis Pharma on 8 of the 15 factors compared between the two stocks.

How does Precision BioSciences compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, suggesting a potential upside of 45.98%. Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 407.08%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ironwood Pharmaceuticals has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.38	$24.02M	$0.77	5.55
Precision BioSciences	$45.06M	3.90	-$45.72M	-$2.80	N/A

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Precision BioSciences' net margin of -96.73%. Ironwood Pharmaceuticals' return on equity of -58.38% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
Precision BioSciences	-96.73%	-72.52%	-32.25%

In the previous week, Ironwood Pharmaceuticals and Ironwood Pharmaceuticals both had 2 articles in the media. Ironwood Pharmaceuticals' average media sentiment score of 0.59 beat Precision BioSciences' score of 0.20 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

38.0% of Precision BioSciences shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Ironwood Pharmaceuticals beats Precision BioSciences on 10 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Silence Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Silence Therapeutics presently has a consensus price target of $53.50, suggesting a potential upside of 364.81%. Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 407.08%. Given Precision BioSciences' higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Precision BioSciences has a net margin of -96.73% compared to Silence Therapeutics' net margin of -8,943.86%. Precision BioSciences' return on equity of -72.52% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Precision BioSciences	-96.73%	-72.52%	-32.25%

In the previous week, Silence Therapeutics and Silence Therapeutics both had 2 articles in the media. Silence Therapeutics' average media sentiment score of 0.25 beat Precision BioSciences' score of 0.20 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precision BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precision BioSciences has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,237.53	-$88.61M	-$1.28	N/A
Precision BioSciences	$45.06M	3.90	-$45.72M	-$2.80	N/A

Summary

Silence Therapeutics beats Precision BioSciences on 8 of the 15 factors compared between the two stocks.

Get Precision BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTIL vs. The Competition

Export

Metric	Precision BioSciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$198.46M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-2.27	13.88	274.09	25.69
Price / Sales	3.90	1,353.16	642.55	79.71
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.58	15.40	10.47	6.32
Net Income	-$45.72M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-4.65%	-1.74%	-0.68%	0.17%
1 Month Performance	-24.73%	-6.20%	-3.18%	-3.27%
1 Year Performance	23.98%	30.64%	15.12%	5.58%

Precision BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTIL Precision BioSciences	2.1819 of 5 stars	$6.36 -11.5%	$32.25 +407.1%	+30.3%	$198.46M	$45.06M	N/A	67	News Coverage
ANNX Annexon	2.5874 of 5 stars	$4.18 -0.9%	$15.14 +262.3%	+33.0%	$792.44M	N/A	N/A	92
VSTM Verastem	3.0632 of 5 stars	$8.37 +4.8%	$13.83 +65.3%	-11.0%	$757.99M	$30.91M	N/A	102
NVCT Nuvectis Pharma	3.5145 of 5 stars	$23.00 +4.6%	$36.25 +57.6%	+251.2%	$750.72M	N/A	N/A	13	Analyst Upgrade
IRWD Ironwood Pharmaceuticals	2.5516 of 5 stars	$4.53 +2.7%	$6.23 +37.6%	+207.2%	$748.54M	$389.32M	5.88	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTIL) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precision BioSciences (DTIL) Competitors

DTIL vs. ANNX, VSTM, NVCT, IRWD, and SLN

How does Precision BioSciences compare to Annexon?

Summary

How does Precision BioSciences compare to Verastem?

Summary

How does Precision BioSciences compare to Nuvectis Pharma?

Summary

How does Precision BioSciences compare to Ironwood Pharmaceuticals?

Summary

How does Precision BioSciences compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precision BioSciences (DTIL) Competitors

DTIL vs. ANNX, VSTM, NVCT, IRWD, and SLN

How does Precision BioSciences compare to Annexon?

Is DTIL or ANNX more profitable?

Which has preferable valuation and earnings, DTIL or ANNX?

Do analysts prefer DTIL or ANNX?

Does the media refer more to DTIL or ANNX?

Which has more volatility and risk, DTIL or ANNX?

Do insiders and institutionals hold more shares of DTIL or ANNX?

Summary

How does Precision BioSciences compare to Verastem?

Do institutionals and insiders believe in VSTM or DTIL?

Which has higher valuation and earnings, VSTM or DTIL?

Is VSTM or DTIL more profitable?

Does the media favor VSTM or DTIL?

Do analysts recommend VSTM or DTIL?

Which has more risk & volatility, VSTM or DTIL?

Summary

How does Precision BioSciences compare to Nuvectis Pharma?

Do analysts prefer NVCT or DTIL?

Which has more volatility and risk, NVCT or DTIL?

Which has better earnings & valuation, NVCT or DTIL?

Is NVCT or DTIL more profitable?

Do insiders & institutionals have more ownership in NVCT or DTIL?

Does the media favor NVCT or DTIL?

Summary

How does Precision BioSciences compare to Ironwood Pharmaceuticals?

Which has more risk & volatility, IRWD or DTIL?

Do analysts rate IRWD or DTIL?

Which has higher earnings & valuation, IRWD or DTIL?

Is IRWD or DTIL more profitable?

Does the media favor IRWD or DTIL?

Do insiders & institutionals have more ownership in IRWD or DTIL?

Summary

How does Precision BioSciences compare to Silence Therapeutics?

Do insiders and institutionals hold more shares of SLN or DTIL?

Which has more volatility and risk, SLN or DTIL?

Do analysts recommend SLN or DTIL?

Is SLN or DTIL more profitable?

Does the media prefer SLN or DTIL?

Which has higher valuation and earnings, SLN or DTIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools